Cancer Treatment

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...

Cancer is a global burden, leading to a significant number of death and disabilities worldwide. In 2020, nearly one in six deaths were related to cancer. Breast cancer, lung cancer, colon and rectum cancer, and prostate cancer are some of the major cancer types, registering the highest number of cases globally. To ...

Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...

Cancer is the second leading cause of death worldwide, after ischemic heart disease. There are approximately 200 different types of cancer, with lung, prostate, colorectal, stomach, and liver cancer being the most common in men and breast, colorectal, lung, cervical, and thyroid cancer being the most common in wome...

Measurable or Minimal Residual Disease (MRD) is a term often used when treating patients with blood cancers. MRD is a small number of cancer cells left in the body after cancer treatment, and these cells can potentially cause relapse in these patients. The number of remaining cells is often too small to cause any s...

Cancer is the world’s second leading cause of death. Every year, 10 million people die from cancer. Cancer kills 70% of people in low-to-middle-income countries. Cancer is estimated to cost the global economy USD 1.16 trillion per year. Millions of lives could be saved annually by implementing resource-appropriate ...

Vivos Therapeutics Received FDA 510(k) Clearance for its Flagship DNA Oral Appliance for the Treatment of Obstructive Sleep Apnea On January 4, 2023, Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mil...

ENHERTU or Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this antibody-drug conjugate (ADC):  A topoisomerase inhibitor that is covalently linked...

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...